|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.890 USD | -0.25% |
|
-8.26% | -10.54% |
| 03-05 | Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target | MT |
| 03-05 | Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing | MT |
Company Valuation: Vanda Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 874.1 | 418.2 | 242.8 | 279.3 | 521.2 | 467.5 | - | - |
| Change | - | -52.16% | -41.95% | 15.04% | 86.62% | -10.3% | - | - |
| Enterprise Value (EV) 1 | 874.1 | 418.2 | 242.8 | 279.3 | 521.2 | 294.3 | 306.5 | 467.5 |
| Change | - | -52.16% | -41.95% | 15.04% | 86.62% | -43.53% | 4.13% | 52.55% |
| P/E ratio | 27.1x | 67.2x | 106x | -14.5x | -2.36x | -3.53x | -9.96x | 182x |
| PBR | - | - | - | - | - | 2.1x | 2.51x | - |
| PEG | - | -0.8x | -1.7x | 0x | -0x | 0.1x | 0.2x | -2x |
| Capitalization / Revenue | 3.25x | 1.64x | 1.26x | 1.41x | 2.41x | 1.82x | 1.32x | 1.03x |
| EV / Revenue | 3.25x | 1.64x | 1.26x | 1.41x | 2.41x | 1.14x | 0.87x | 1.03x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 20.7x | 66.1x | -17.4x | -6.87x | -3.45x | -1.83x | -4.3x | -319x |
| EV / FCF | - | - | - | -13.6x | -4.72x | -2.2x | -5.8x | 62.3x |
| FCF Yield | - | - | - | -7.33% | -21.2% | -45.4% | -17.2% | 1.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.58 | 0.11 | 0.04 | -0.33 | -3.74 | -2.236 | -0.792 | 0.0433 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 268.7 | 254.4 | 192.6 | 198.8 | 216.1 | 257.1 | 353.3 | 453.8 |
| EBITDA | 45.01 | - | - | - | - | - | - | - |
| EBIT 1 | 42.16 | 6.329 | -13.95 | -40.66 | -151.2 | -160.7 | -71.22 | -1.467 |
| Net income 1 | 33.15 | 6.275 | 2.509 | -18.9 | -220.5 | -133.5 | -55.5 | -1 |
| Net Debt 1 | - | - | - | - | - | -173.2 | -161.1 | - |
| Reference price 2 | 15.690 | 7.390 | 4.220 | 4.790 | 8.820 | 7.890 | 7.890 | 7.890 |
| Nbr of stocks (in thousands) | 55,712 | 56,590 | 57,532 | 58,308 | 59,097 | 59,108 | - | - |
| Announcement Date | 23/02/22 | 08/02/23 | 07/02/24 | 13/02/25 | 11/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.54x | 1.14x | - | - | 468M | |
| 42.29x | 9.88x | 35.66x | 0.03% | 44.3B | |
| 15.95x | 5.66x | 12.46x | 1.87% | 40B | |
| -53.27x | 18x | -59.42x | -.--% | 30.95B | |
| -25.81x | 4.24x | -11.69x | -.--% | 25.58B | |
| 27.26x | 5.62x | 15.59x | -.--% | 18.76B | |
| 22.65x | 4.6x | 16.19x | -.--% | 16.89B | |
| -293.35x | 24.23x | 1418.21x | -.--% | 12.02B | |
| -12.51x | 5937.57x | -16.97x | -.--% | 11.58B | |
| -154.44x | 37.64x | -149.51x | -.--% | 11.03B | |
| Average | -43.48x | 604.86x | 140.06x | 0.21% | 21.16B | |
| Weighted average by Cap. | -20.23x | 335.58x | 74.41x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- VNDA Stock
- Valuation Vanda Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition